RECKITT BENCKISER
SpecialtyRECKITT BENCKISER is a specialty pharmaceutical company focused on Gastroenterology, Infectious Disease, Dermatology. Key products include MUCINEX 12HR COLD & FEVER MULTI-SYMPTOM.
RECKITT BENCKISER at a Glance
- Strong track record with 87% execution quality across 17 trials
- Fast trial execution (5 months median completion)
RECKITT BENCKISER's Key Drugs
RECKITT BENCKISER's core commercial portfolio centers on MUCINEX 12HR COLD & FEVER MULTI-SYMPTOM, spanning Gastroenterology and Infectious Disease — its most strategically important drugs approved in the last 15 years.
RECKITT BENCKISER's Recent FDA Approvals
RECKITT BENCKISER secured 1 new FDA approval for novel drugs (NDA/BLA) in the last two years.
RECKITT BENCKISER's Therapeutic Areas
RECKITT BENCKISER's approved drugs and pipeline span 3 therapeutic areas, led by Gastroenterology and Infectious Disease, across 0 biologic and 5 small-molecule drugs. Weighted by commercial stage — approved drugs count most, then late-stage trials.
RECKITT BENCKISER's Top Competitors
RECKITT BENCKISER's closest competitors by therapeutic-area and drug-target overlap include APOTHECON, Pfizer, and PF PRISM CV. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.
RECKITT BENCKISER Pipeline Snapshot
RECKITT BENCKISER has 8 active clinical programs from ClinicalTrials.gov — 2 Phase 3, 2 Phase 2 and 4 Phase 1.
Pro Intelligence Preview
Deep insights for investors and analysts
Revenue Insights
- • MUCINEX 12HR COLD & FEVER MULTI-SYMPTOM leads revenue
- • Drug-level revenue analysis
Trial Catalysts
- • Gastroenterology pipeline focus
- • Phase 3 readout tracking
Patent Risk
- • Patent expiration timeline
- • Revenue at risk analysis
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Execution Intelligence
- • Phase 3: 6/7 completed
- • Speed: 5 months avg
Revenue forecasts • Trial milestones • Patent risk modeling
Active (1)
Discontinued (0)
Company Info
- First Approval
- 1982-10-08
- Latest
- 2025-12-22
- Applications
- 5
How We Calculate These Metrics
Execution Quality Score
Measures trial completion rates weighted by phase importance. Phase 3 trials count 4x more than Phase 1 because late-stage completion is harder and more valuable.
What counts as "completed": A trial that reached its planned endpoint and reported results. Trials that were terminated early, withdrawn, or suspended are not counted as completed—these often indicate safety issues, lack of efficacy, or strategic pivots.
- Excellent (80%+): Top-tier execution, most trials reach planned endpoints
- Good (60-79%): Strong execution with occasional early terminations
- Fair (40-59%): Average execution, notable rate of terminated/withdrawn trials
- Needs Improvement (under 40%): High termination rates, execution challenges